It is hoped that Novavax’s protein-based, and thus more traditional, vaccine could persuade holdouts who worry about the current mRNA vaccine’s safety profile to take the plunge. It would add a fifth vaccine to the EU’s arsenal, next to those of Pfizer-BioNTech, Moderna, AstraZeneca and Johnson & Johnson.